Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ovid Therapeutics (OVID : NSDQ)
 
 • Company Description   
Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved in developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid Therapeutics Inc. is based in New York, United States.

Number of Employees: 57

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.12 Daily Weekly Monthly
20 Day Moving Average: 100,673 shares
Shares Outstanding: 70.42 (millions)
Market Capitalization: $149.29 (millions)
Beta: 1.56
52 Week High: $4.80
52 Week Low: $2.08
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -33.75% -27.41%
12 Week -34.16% -28.56%
Year To Date -33.96% -21.46%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1460 Broadway Suite 15044
-
New York,NY 10036
USA
ph: 646-661-7661
fax: -
investors@ovidrx.com http://www.ovidrx.com
 
 • General Corporate Information   
Officers
Jeremy M. Levin - Chief Executive Officer
Jeffrey Rona - Chief Business and Financial Officer
Karen Bernstein - Director
Barbara Duncan - Director
Bart Friedman - Director

Peer Information
Ovid Therapeutics (CORR.)
Ovid Therapeutics (RSPI)
Ovid Therapeutics (CGXP)
Ovid Therapeutics (BGEN)
Ovid Therapeutics (GTBP)
Ovid Therapeutics (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 690469101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 70.42
Most Recent Split Date: (:1)
Beta: 1.56
Market Capitalization: $149.29 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.98 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.90
Price/Cash Flow: 1.17
Price / Sales: -
EPS Growth
vs. Year Ago Period: -109.09%
vs. Previous Quarter: 39.47%
Sales Growth
vs. Year Ago Period: -99.31%
vs. Previous Quarter: -%
ROE
03/31/22 - -37.03
12/31/21 - 61.07
09/30/21 - 75.88
ROA
03/31/22 - -34.18
12/31/21 - 57.33
09/30/21 - 68.69
Current Ratio
03/31/22 - 16.63
12/31/21 - 12.87
09/30/21 - 20.38
Quick Ratio
03/31/22 - 16.63
12/31/21 - 12.87
09/30/21 - 20.38
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -4,733.77
12/31/21 - 59.58
09/30/21 - 60.01
Book Value
03/31/22 - 2.34
12/31/21 - 2.64
09/30/21 - 2.90
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.10
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 8.78
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©